| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Total revenues | ||||||||||
3,049 | 22,146 | 6,000 | - | - | - | - | - | - | - | - |
Collaboration revenue | ||||||||||
- | - | - | 18,723 | 109,066 | 164,995 | - | - | - | - | - |
Collaboration revenue | ||||||||||
- | - | - | - | - | - | - | 47,114 | - | - | - |
Collaborative research and development revenue from Purdue entities | ||||||||||
- | - | - | - | - | - | - | - | 92,773 | 71,331 | 50,765 |
Operating expenses: | ||||||||||
Research and development | ||||||||||
27,116 | 19,758 | 20,830 | 119,611 | 199,109 | 143,633 | 99,760 | 118,595 | 108,582 | 99,232 | 77,856 |
General and administrative | ||||||||||
14,289 | 14,248 | 21,615 | 42,219 | 37,065 | 29,285 | 27,916 | 27,882 | 22,719 | 21,070 | 19,456 |
Royalty expense | ||||||||||
7,308 | 69 | 0 | - | - | - | - | - | - | - | - |
Total operating expenses | ||||||||||
48,713 | 34,075 | 42,445 | 161,830 | 236,174 | 172,918 | 127,676 | 146,477 | 131,301 | 120,302 | 97,313 |
Gain on AbbVie Opt-Out (note 11) | ||||||||||
- | - | - | 112,216 | 0 | 0 | - | - | - | - | - |
Gain on termination of Purdue entities alliance | ||||||||||
- | - | - | - | - | - | - | 46,555 | - | - | - |
Loss from operations | ||||||||||
-45,664 | -11,929 | -36,445 | -30,891 | -127,108 | -7,923 | -127,676 | -52,808 | -38,528 | -48,971 | -46,547 |
Other income (expense): | ||||||||||
Investment and other income | ||||||||||
1,116 | 769 | - | - | - | - | - | - | - | - | - |
Other income (expense): | ||||||||||
Income from Massachusetts tax incentive award | ||||||||||
- | - | - | - | - | - | - | 193 | - | - | - |
Investment and other income | ||||||||||
- | - | 1,787 | 2,015 | 435 | 339 | 896 | 559 | - | - | - |
Interest expense (note 9) | ||||||||||
2,563 | 93 | 1,010 | 1,225 | 1,368 | 9,649 | - | 1,908 | 1,841 | 1,910 | 1,300 |
Other Nonoperating Expense | ||||||||||
- | - | 6,900 | 0 | 0 | - | - | - | - | - | - |
Investment and other income | ||||||||||
- | - | - | - | - | - | - | - | 327 | - | - |
Income from NIH reimbursement | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,745 |
Income from residual funding after reacquisition of Hsp90 program | ||||||||||
- | - | - | - | - | - | - | - | - | - | 12,450 |
Income from Therapeutic Discovery Grants | ||||||||||
- | - | - | - | - | - | - | - | - | 734 | - |
Interest and investment income | ||||||||||
- | - | - | - | - | - | - | - | - | 463 | 2,044 |
Total other expense | ||||||||||
-1,447 | 676 | -6,105 | 790 | -933 | -9,310 | 896 | -1,156 | -1,514 | -713 | 14,939 |
Loss before income taxes | ||||||||||
-47,111 | -11,253 | -42,550 | -30,101 | -128,041 | -17,233 | -126,780 | -53,964 | -40,042 | -49,684 | -31,608 |
Income taxes benefit | ||||||||||
-54 | 0 | -700 | 0 | 335 | 183 | 0 | 0 | 0 | -700 | -329 |
Net Income (Loss) Attributable to Parent | ||||||||||
-47,057 | -11,253 | -41,830 | -30,101 | -128,376 | -17,416 | -126,780 | -53,964 | -40,042 | -48,984 | -31,278 |
Basic and diluted loss per common share (in dollars per share) | ||||||||||
-0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.20 |
Basic and diluted weighted average number of common shares outstanding (in shares) | ||||||||||
56,983 | 55,411 | 50,560 | 49,608 | 49,083 | 48,561 | 47,936 | 31,711 | 26,620 | 26,321 | - |
Other comprehensive loss: | ||||||||||
Basic and diluted weighted average number of common shares outstanding | ||||||||||
- | - | - | - | - | - | - | - | - | - | 26,096 |
Net unrealized holding gains on available-for-sale securities arising during the period | ||||||||||
16 | 11 | -12 | -48 | -69 | -42 | 22 | 112 | -32 | 17 | - |
Comprehensive loss | ||||||||||
-47,041 | -11,242 | -41,842 | -30,149 | -128,445 | -17,458 | -126,758 | -53,852 | -40,074 | -48,967 | - |
Collaboration revenue | ||||||||||
Total revenues | ||||||||||
2,000 | 22,000 | 6,000 | - | - | - | - | - | - | - | - |
Royalty revenue | ||||||||||
Total revenues | ||||||||||
1,049 | 146 | 0 | - | - | - | - | - | - | - | - |